Real World Experience
with EYLEA® (aflibercept) 8 mg
Explore real world clinician experience of implementing treatment with EYLEA® (aflibercept) 8 mg in the UK. These resources highlight the potential of EYLEA 8 mg to address unmet needs in the treatment of nAMD and DMO.
UK Audits of EYLEA 8 mg Treatment for Patients with nAMD
Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust
In this video, Serena Salvatore presents the drying effects of EYLEA 8 mg from an audit conducted at Bristol Eye Hospital. The video discusses the results of treating 352 naïve patients with EYLEA 8 mg.
- Duration: 8 minutes
- Treatment-naïve patients
- nAMD
Prescribing information for EYLEA® (aflibercept) can be found here.
This downloadable booklet presents outcomes from UK case studies conducted at:
- Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust
- Newmedica Eye Health Clinic & Surgical Centre, Grimsby
- Western Eye Hospital, Imperial College Healthcare NHS Trust
nAMD and DMO Patient Case Study Discussion ~30 minutes
Features Richard Gale, Hani Hasan and Rossella Anzidei, each presenting up to two cases of patients with neovascular age related macular degeneration or visual impairment due to diabetic macular oedema treated with EYLEA 8 mg. The management of each case is then discussed by the panel.
Prescribing information for EYLEA® (aflibercept) can be found here.
Please refer to the links below to hear from other experts who have used EYLEA 8 mg, and explore a variety of on-demand resources created in collaboration with both local and internationally recognised leaders in medical retina.
Abbreviations
DMO, diabetic macular oedema. nAMD, neovascular (wet) age-related macular degeneration. NHS, National Health Service.
PP-EYL-GB-2790 | March 2025